MOL2150 Simplexa HSV 1&2 Direct -CSF -Genital Swab -Cutaneous / Mucocutaneous Swabs Product Usage...

FDA Device Recall #Z-2547-2020 — Class II — May 12, 2020

Recall Summary

Recall Number Z-2547-2020
Classification Class II — Moderate risk
Date Initiated May 12, 2020
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm DiaSorin Molecular LLC
Location Cypress, CA
Product Type Devices
Quantity 13943 plastic vials (24 vials per box)

Product Description

MOL2150 Simplexa HSV 1&2 Direct -CSF -Genital Swab -Cutaneous / Mucocutaneous Swabs Product Usage: is intended for use on the LIAISON MDX instrument for the qualitative detection and differentiation of HSV-1 and HSV-2 present in cerebrospinal fluid (CSF), or cutaneous and mucocutaneous lesion swabs from patients with signs and symptoms of HSV-1 or HSV-2 infection of the central nervous system (CNS) or cutaneous and mucocutaneous lesions.

Reason for Recall

Due to a software malfunction in the Multi Assay Suite, there is the probability of increased occurrence of false negative results.

Distribution Pattern

Worldwide distribution - U.S. Nationwide distribution including in the states of CO, FL, KS, MI, NC, PA, TX, and WA The countries of Austria, Czech Republic, France and Switerland.

Lot / Code Information

MOL2150 Simplexa HSV 1&2 Direct: Lot Numbers Release Date Exp Date 3606N 08/16/18 6/30/2020 3607N 08/31/18 6/30/2020 3609N 08/31/18 6/30/2020 3610N 10/08/18 7/31/2020 3615N 01/07/19 6/30/2020 3616N 11/28/18 6/30/2020 3618N 12/26/18 6/30/2020 3619N 12/26/18 6/30/2020 3847N 12/31/18 6/30/2020 3998N 07/20/18 5/31/2020 4000N 07/18/18 5/31/2020 4130N 03/05/19 6/30/2020 4131N 02/01/19 6/30/2020 4132N 02/15/19 6/30/2020 4134N 04/18/19 8/31/2020 4137N 04/04/19 8/30/2020 4138N 04/30/19 8/31/2020 4139N 07/12/19 5/31/2021 5171N 09/17/19 6/30/2021 5172N 09/03/19 6/30/2021 5173N 05/03/19 8/31/2020 5174N 06/04/19 8/31/2020 5175N 06/04/19 8/31/2020 5187N 07/19/19 5/31/2021 5188N 06/05/19 8/31/2020 5189N 07/25/19 5/31/2021 5190N 05/23/19 8/31/2020 5623N 07/25/19 5/31/2021 5738N 08/02/19 5/31/2021 5739N 08/20/19 6/30/2021 5793N 10/07/19 7/31/2021 5795N 03/09/20 12/31/2021 5841N 10/22/19 8/31/2021 5843N 10/31/19 8/31/2021 5845N 10/18/19 8/31/2021 5846N 04/06/20 1/31/2022 5846NA 04/16/20 1/31/2022 5847N 12/17/19 10/31/2021 5878N 03/11/20 1/31/2022 5888N 03/18/20 1/31/2022 R5170N 06/20/19 8/31/2020 R5201N 06/28/19 8/31/2020 R5202N 07/03/19 4/30/2021 R5283N 08/13/19 8/31/2020 R5285N 06/20/19 8/31/2020

Other Recalls from DiaSorin Molecular LLC

Recall # Classification Product Date
Z-2153-2023 Class II Simplexa Direct Amplification Disc Kit, Rx Only... Jun 14, 2023
Z-1209-2023 Class II Simplexa COVID-19 Direct, REF: MOL4150; includi... Jan 30, 2023
Z-1210-2023 Class II Simplexa Flu A/B & RSV Direct Gen II, REF: MOL2... Jan 30, 2023
Z-0457-2022 Class II Simplexa Direct Amplification Disc Kit, Product... Nov 19, 2021
Z-0162-2022 Class II SIMPLEXA COVID-19 Positive Control Pack, REF MO... Sep 23, 2021

Frequently Asked Questions

A software recall means the device's embedded software or firmware has a defect that could affect its performance or safety. Many software recalls are corrected through firmware updates that can be applied without physically replacing the device. For implantable devices, the update may be delivered wirelessly during a routine clinic visit. For external devices, the manufacturer may provide updated software files or replacement units. Contact your healthcare provider to determine whether your specific device and software version are affected and what action is recommended.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.